Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;35(6):150957.
doi: 10.1016/j.soncn.2019.150957. Epub 2019 Nov 20.

Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia

Daniel R Richardson  1 , Matthew C Foster  2 , Catherine C Coombs  2 , Joshua F Zeidner  2
Affiliations
Review

Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia

Daniel R Richardson et al. Semin Oncol Nurs. 2019 Dec.

Abstract

Objective: To review the current state of molecular and genetic profiling of acute myeloid leukemia (AML) and its implications.

Data source: Peer-reviewed journal articles.

Conclusion: Significant advances in the understanding of the pathology of acute myeloid leukemia have led to refined risk stratification of patients and application of novel targeted therapies based on genetic profiles. Minimal residual disease testing allows for highly sensitive disease surveillance that can be used to predict relapse and assess treatment response.

Implications for nursing practice: Accurate prognostication and therapeutic decision-making for patients with acute myeloid leukemia is dependent on molecular profiling. Being knowledgeable of the implications of minimal residual disease testing is critical for patient-centered care.

Keywords: acute myeloid leukemia (AML); genetics; minimal residual disease (MRD); molecular targeted therapies; mutations prognosis.

PubMed Disclaimer

References

    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152. - PubMed
    1. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605–1616. - PubMed
    1. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320. - PubMed
    1. Falini B, Martelli MP. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. Best Pract Res. Clin Haematol. 2015;28:90–97. - PubMed
    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127: 2391–2405. - PubMed

Publication types